18 L1 type 16 human papillomavirus vaccine (Cervarix)

Subscribe to Selected New Research on 18 L1 type 16 human papillomavirus vaccine

19 relevant articles (6 outcomes, 1 trials/studies) found for this Bio-Agent

Description: vaccine containing L1 capsid proteins from types 16 and 18 of HPV (ALPHAPAPILLOMAVIRUS)

Also Known As:

Cervarix; human papillomavirus vaccine, L1 type 16, 18; GSK brand of HPV bivalent vaccine; HPV L1 vaccine, bivalent 16,18; human papillomavirus vaccine L1 16,18

Relationship Network

Bio-Agent Context: Research Results

Complex Mixtures: 297

Biological Products

Vaccines: 14106

Viral Vaccines: 136

Papillomavirus Vaccines: 171

18 L1 type 16 human papillomavirus vaccine: 19

Experts

1.	Harper, Diane M: 1 article (09/2008)
2.	Duh, D: 1 article (03/2008)
3.	Vandevijver, A: 1 article (03/2008)
4.	Crosbie, Emma J: 1 article (03/2007)
5.	Kitchener, Henry C: 1 article (03/2007)

Related Diseases

1.	Infection 09/01/2008 - "Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age." 07/01/2008 - "The second is a bivalent vaccine preventing infection from 2 high-risk oncogenic HPV types (HPV types 16 and 18) (Cervarix)" 09/01/2008 - "The AS04-adjuvanted vaccine Cervarix was developed against HPV-16 and -18 focusing on preventing cervical cancer by inducing durable protection against new infection" 09/01/2007 - "The quadrivalent HPV VLP 6, 11, 16, 18 vaccine (Gardasil) and the bivalent HPV VLP 16, 18 vaccine (Cervarix) are effective for prevention of HPV infection and cervical precancerous lesions" 07/01/2006 - "CONCLUSIONS: Cervarix and Gardasil are effective for prevention of HPV infection and cervical lesions" Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 11/01/2008 - "Here, we compare both the direct ELISA and the single epitope-based inhibition ELISA with the pseudovirion-based neutralization assay (PBNA) for HPV-16/18 antibody responses in vaccinated women enrolled in trials of Cervarix, GSK's cervical cancer vaccine" 05/01/2008 - "Cervarix is a recombinant cervical cancer vaccine recently developed by GlaxoSmithKline Biologicals (Rixensart, Belgium)" 03/01/2007 - "The clinical experience of Cervarix and its potential role in reducing the global burden of cervical cancer is discussed." 03/01/2007 - "Cervarix--a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer." 01/01/2007 - "The other (Cervarix) contains types 16 and 18, targeting cervical cancer alone" Get all the results and reference details, order at left...
3.	Condylomata Acuminata (Genital Wart) 12/01/2007 - "The two new HPV vaccines (Gardasil quadrivalent and Cervarix bivalent 16,11) are both effective against HPV types 16 and 18, which are responsible for 70% of cervical cancers, and the quadrivalent vaccine is effective against HPV 6 and 11, responsible for genital warts" Get all the results and reference details, order at left...
4.	Papilloma (Papillomatosis) 03/01/2008 - "Human papilloma virus vaccine (Cervarix)]" 10/01/2005 - "Cervarix would prevent human papilloma virus which can lead to cervical cancer; FDA approval anticipated." Get all the results and reference details, order at left...
5.	Malaria 02/01/2008 - "Licensed vaccines with second generation of adjuvant systems are Cervarix and Fendrix vaccines and in development are vaccines against malaria and genital herpes" Get all the results and reference details, order at left...
6 Diseases and 19 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	type 6,11,16,18 human papillomavirus vaccine L1 (Gardasil)
2.	Vaccines
3.	Papillomavirus Vaccines (HPV Vaccines)
4.	Fendrix
4 Drugs and Important Bio-Agents and 9 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>